In last trading session, Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) saw 14.25 million shares changing hands with its beta currently measuring 0.63. Company’s recent per share price level of $16.01 trading at -$0.03 or -0.19% at ring of the bell on the day assigns it a market valuation of $18.36B. That closing price of TEVA’s stock is at a discount of -42.41% from its 52-week high price of $22.80 and is indicating a premium of 22.11% from its 52-week low price of $12.47. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 9.48 million shares which gives us an average trading volume of 11.56 million if we extend that period to 3-months.
For Teva- Pharmaceutical Industries Ltd. ADR (TEVA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 8 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) trade information
Upright in the red during last session for losing -0.19%, in the last five days TEVA remained trading in the red while hitting it’s week-highest on Thursday, 07/10/25 when the stock touched $16.01 price level, adding 4.53% to its value on the day. Teva- Pharmaceutical Industries Ltd. ADR’s shares saw a change of -7.35% in year-to-date performance and have moved -4.19% in past 5-day. Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) showed a performance of -5.77% in past 30-days. Number of shares sold short was 40.0 million shares which calculate 3.61 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 22 to the stock, which implies a rise of 27.23% to its current value. Analysts have been projecting 10 as a low price target for the stock while placing it at a high target of 28. It follows that stock’s current price would jump 37.54% in reaching the projected high whereas dropping to the targeted low would mean a gain of 37.54% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -9.62% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 1.91% while estimates for its earnings growth in next 5 years are of 7.80%.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA)’s Major holders
Insiders are in possession of 0.00% of company’s total shares while institution are holding 64.52 percent of that, with stock having share float percentage of 64.52%. Investors also watch the number of corporate investors in a company very closely, which is 64.52% institutions for Teva- Pharmaceutical Industries Ltd. ADR that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at TEVA for having 42.99 million shares of worth $698.55 million. And as of 2024-06-30, it was holding 3.7942 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 41.98 million shares on 2024-06-30. The number of shares represents firm’s hold over 3.7051 of outstanding shares, having a total worth of $682.15 million.
On the other hand, Fidelity Contrafund and iShares Trust-iShares Core MSCI EAFE ETF are the top two Mutual Funds which own company’s shares. As of May 31, 2025 , the former fund manager was holding 17.36 shares of worth $277.89 million or 1.51% of the total outstanding shares. The later fund manager was in possession of 7.36 shares on May 31, 2025 , making its stake of worth around $117.91 million in the company or a holder of 0.64% of company’s stock.
